Associate Professor, Medicine, University of Miami Leonard M. Miller School of Medicine
Hematology
Dr. Edgardo Santos, MD
|
|
Give Review
Edgardo Santos is an expert in the field of Hematology. He received awards:"CMS Meaningful Use Stage 1 Certification". Edgardo Santos is a published doctor. He published 50 publications, including: 'Clinical effects of intermittent, intravenous cyclophosphamide in severe systemic lupus erythematosus.' Edgardo Santos accepts Medicare payments and is listed with Medicare.gov.
Publications
- Central Nervous system toxicities of chemotherapeutic agents.
- Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation.
- A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous Cell histolo...
- Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck Cancer.
- Prognostic factors of the results of cardiopulmonary resuscitation in a cardiology hospital.
- Clinical effects of intermittent, intravenous cyclophosphamide in severe Systemic lupus erythematosus.
- Survival of renal allograft following de novo hemolytic uremic Syndrome after kidney transplantation.
- A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal Cancer.
- Prevalence of hepatitis C infection in patients with non-Hodgkin''s Lymphoma in South Florida and review of the literature.
- A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-nega...
- Autologous transplantation for relapsed non-Hodgkin''s Lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience.
- Controversies in the management of stage IIIA non-small-cell lung Cancer.
- Targeting important pathways in head and neck Cancer: from the bench to the clinic.
- Active immunotherapy for non-small-cell lung Cancer: moving toward a reality.
- Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic Carcinoma metastatic to the lung: case report and review of literature.
- Biomarkers, prediction, and prognosis in non-small-cell lung Cancer: a platform for personalized treatment.
- Systemic lupus erythematosus presenting as thrombotic thrombocytopenia purpura: how close is close enough?
- The role of proteasome inhibition in nonsmall cell lung Cancer.
- Development of targeted therapy for squamous Cell carcinomas of the head and neck.
- EGF receptor in lung Cancer: a successful story of targeted therapy.
- Cancer vaccines: a new therapeutic alternative for lung Cancer therapy?
- Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC.
- Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung Cancer.
- Nasopharyngeal Carcinoma: alternative treatment options after disease progression.
- Oxaliplatin in first-line therapy for advanced non-small-cell lung Cancer.
- Developing a vaccine for non-small-cell lung Cancer. Commentary.
- How is gene-expression profiling going to challenge the future management of lung Cancer?
- Gene expression profiling and non-small-cell lung Cancer: where are we now?
- Second-line therapy for non-small-cell lung Cancer.
- Hematopoietic cell transplantation for chronic lymphocytic Leukemia: an evolving concept.
- Rituximab and its role as maintenance therapy in non-Hodgkin Lymphoma.
- Current results and future applications of radioimmunotherapy management of non-Hodgkin''s Lymphoma.
- New horizons in multiple myeloma therapy.
- Induction chemotherapy in the management of squamous Cell carcinoma of the head and neck.
- Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung Cancer (NSCLC).
- Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature.
- Revisiting the role of hematopoietic stem cell transplantation in chronic lymphocytic Leukemia.
- DNA methylation: its role in Lung carcinogenesis and therapeutic implications.
- Clinical trials targeting lung Cancer with active immunotherapy: the scope of vaccines.
- Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive Acute lymphoblastic leukemia.
- Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic Leukemia.
- New targets for non-small-cell lung Cancer therapy.
- Hematopoietic cell transplantation in Acute promyelocytic leukemia: a comprehensive review.
- The utility of a bone marrow biopsy in diagnosing the source of fever of unknown origin in patients with AIDS.
- Role of farnesyltransferase inhibitors in hematologic malignancies.
- Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung Cancer--experience from a prematurely closed phase II study.
- Thalidomide effects in the post-transplantation setting in patients with multiple myeloma.
- Primary hepatic non-Hodgkin's Lymphomas: case report and review of the literature.
- Life-threatening bleeding from refractory acquired FVIII inhibitor successfully treated with rituximab.
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Jackson Memorial Hospital - Jackson Health System -
Universidad de Panama Faculty of Medicine
Drug Facts
| NPI NUMBER | 1639260771 | |
| NPPES Provider LastName | SANTOS | |
| NPPES Provider FirstName | EDGARDO | |
| NPPES Provider ZIPCode | 701122600 | |
| NPPES Provider State | LA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 104.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1639260771 |
| Last Name Of The Provider | SANTOS |
| First Name Of The Provider | EDGARDO |
| View All |
Similar Doctors
|
|
Dr. Milton W. Seiler Jr., MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. John T. Cole, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marc J. Kahn, MD |
|
Dr. Charles V. Wendling Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cindy A. Leissinger, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Li Huang, MD |
|
Dr. Brian Boulmay, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gary E. Lipscomb, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sukanthini Subbiah, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ali Baghian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lee R. Morgan Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rubina H. Khan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sachin G. Pai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nancy S. Vander Velde, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert Weilbaecher Sr., MD |
|
|
Dr. Michelle M. Loch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kamal K. Mandalapu, MD |